In ASCVD, moderate-intensity statin + ezetimibe was noninferior to high-intensity statin alone at 3 y

Ann Intern Med. 2022 Nov;175(11):JC126. doi: 10.7326/J22-0085. Epub 2022 Nov 1.

Abstract

Kim BK, Hong SJ, Lee YJ, et al. Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial. Lancet. 202;400:380-90. 35863366.

Publication types

  • Comment

MeSH terms

  • Anticholesteremic Agents / therapeutic use
  • Atherosclerosis* / drug therapy
  • Drug Therapy, Combination / adverse effects
  • Equivalence Trials as Topic
  • Ezetimibe* / therapeutic use
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors* / therapeutic use
  • Randomized Controlled Trials as Topic
  • Treatment Outcome

Substances

  • Anticholesteremic Agents
  • Ezetimibe
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors